Investigating renal tissue responses to radiopharmaceutical therapy using multiparametric MRI

Authors:

Abstract
Objectives Renal toxicity is a recognized potential adverse effect of radiopharmaceutical therapy (RPT). While 177 Lu-based therapies are generally well tolerated, subtle therapy-related renal changes remain insufficiently characterized. This study investigated longitudinal renal alterations during 177 Lu-based RPT using multiparametric magnetic resonance imaging (mpMRI) and evaluated its potential for renal monitoring. Methods Twenty-three patients undergoing RPT with either [ 177 Lu]Lu-DOTATATE (n = 14) or [ 177 Lu]Lu-PSMA (n = 9) underwent renal mpMRI examinations before and during therapy with up to four treatment cycles. Imaging included arterial spin labeling, diffusion-weighted imaging with intravoxel incoherent motion analysis, blood oxygenation level-dependent imaging, T1 mapping, and volumetry. Renal scintigraphy, estimated glomerular filtration rate (eGFR), and absorbed renal radiation dose were assessed longitudinally. Results No significant decline in eGFR was observed during RPT after exclusion of two patients who developed urinary tract obstruction (p = 0.19). Longitudinal analysis revealed significant temporal changes in T1 values (p = 0.008) and perfusion fraction of IVIM (p = 0.005), as well as a modest decrease in the corticomedullary BOLD ratio (p = 0.020). No significant longitudinal changes were detected for other MRI or scintigraphic parameters. Absorbed renal radiation dose was not associated with changes in MRI-derived biomarkers, eGFR, or renal scintigraphy (all p > 0.05). Patients with urinary obstruction demonstrated distinct MRI abnormalities, including reduced renal blood flow (RBF) and altered BOLD metrics. Conclusions No clinically relevant renal functional deterioration or major imaging abnormalities were detected during contemporary 177 Lu-based RPT. Subtle longitudinal T1 increases may reflect mild structural tissue remodeling without measurable functional consequences. Renal mpMRI is feasible for non-invasive monitoring and may provide complementary information beyond conventional renal function assessment. Trial registration, DRKS, DRKS00018966, registered 10 October 2019; https://www.drks.de/search/de/results

This publication has 45 references indexed in Scilit: